BGI said it will make more details about the BGISEQ-500 instrument available at the 10th International Conference on Genomics in Shenzhen in October.
Complete Genomics is targeting its $12 million fully automated Revolocity system at the clinical market and has already secured its first two customers.
B10K builds on a previous project that provided proof of concept for carrying out large-scale sequencing of multiple representative species across a vertebrate class.
The scientists combined whole-genome shotgun and fosmid pool sequencing, using next-generation sequencing technology from Illumina and BGI's Complete Genomics.
The partners received £30,000 (about $46,000) in funding from the BBSRC to support their metabolomics data-sharing and analyses activities.
BGI will provide Qiagen's Ingenuity Variant Analysis software in integrated bioinformatics for all customers of its sequencing services.
Chinese regulators approved BGI's clinical laboratories in Shenzhen and Tianjin to conduct high-throughput clinical genetic testing services for cancer.
Three new studies, published online in the New England Journal of Medicine, shed light on how NIPT may be best integrated into clinical care for all pregnant women.
The Financial Times' Henny Sender writes that BGI is a new kind of Chinese technology company.
The method could have future applications in preimplantation genetic diagnosis and circulating tumor cell analysis.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.